Korea Zinc Announces EGM Results, Affirming the Important Position the Company Holds in National Key Industry
SEOUL, South Korea, Jan. 24, 2025 /PRNewswire/ -- On January 23, Korea Zinc (KRX:010130) held an extraordinary general meeting (EGM) at Grand Hyatt Seoul to vote on eight agenda items proposed for amendments to the company's articles. Among these,...
Kelun-Biotech's Product Tagitanlimab Approved for Marketing in Second Indication in Combination with Cisplatin and Gemcitabine For the First-line Treatment of Patients with recurrent or metastatic NPC
CHENGDU, China, Jan. 23, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization in China from National Medical Products Administration (NMPA) for the...
Purchasers of Quantstamp QSP Tokens May Be Eligible for Payment from the Quantstamp Fair Fund
COSTA MESA, Calif., Jan. 22, 2025 /PRNewswire/ -- The following statement is being issued by Simpluris, Inc., the SEC-appointed Fund Administrator. UNITED STATES OF AMERICA Before the SECURITIES AND EXCHANGE COMMISSION In the Matter of Quantstamp,...
Breaking Down Silos: IQAX eBL Interoperability Approved by IG P&I Clubs
HONG KONG, Jan. 22, 2025 /PRNewswire/ -- IQAX Limited's electronic bill of lading (eBL) solution has received approval from the International Group of P&I Clubs (IG P&I Clubs) for IQAX eBL interoperable addendum (version dated 6 December...
The Moskowitz Law Firm, PLLC Announces Preliminary Approval of a Proposed Class Action Settlement on Behalf of Purchasers of Astrals Non-Fungible Tokens and Galaxy Tokens
MIAMI, Jan. 18, 2025 /PRNewswire/ -- The Moskowitz Law Firm, PLLC announces the preliminary approval of a proposed class action settlement that would benefit purchasers and legal title holders of Astrals Non-Fungible Tokens or Galaxy Tokens: On...
Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer
SHANGHAI, Jan. 17, 2025 /PRNewswire/ -- IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, is pleased to announce that Senaparib...
Thailand Approves Update of Long-Term Resident (LTR) Visa's Criteria and Conditions to Attract a Wider Range of Foreign Experts, Investors, and Executives
BANGKOK, Jan. 15, 2025 /PRNewswire/ -- The Thailand Board of Investment (BOI) announced today the approval by the Cabinet of updates and adjustments to the qualifications, criteria, and conditions for the Long-Term Resident (LTR) Visa program to...
ImmunoForge Receives IND Approval for Phase 2 Clinical Trial of 'Pemziviptadil' for DMD Cardiomyopathy Treatment from FDA, and KF1601, a chronic myeloid leukemia treatment, phase 1 clinical trial IND approved by MFDS
SEOUL, South Korea, Jan. 14, 2025 /PRNewswire/ -- ImmunoForge announced that it has received approval for the Phase 2 clinical trial IND for 'Pemziviptadil (development code name PF1804),' a treatment for DMD (Duchenne Muscular Dystrophy)...
QNB Group : Financial Results For The Year Ended 31 December 2024
DOHA, Qatar, Jan. 13, 2025 /PRNewswire/ -- QNB Group, one of the largest financial institution in the Middle East and Africa (MEA) region, announced that the Board of Directors, during its meeting held today has approved its results for the year...
Thailand BOI Says 2024 Investment Applications Soar 35% to 10-Year High of USD33 Billion as FDI in Data Centers and Cloud Services Take the Lead
BANGKOK, Jan. 13, 2025 /PRNewswire/ -- The Thailand Board of Investment (BOI) said today that applications for investment promotion in 2024 soared 35% in value to 1.14 trillion baht (ca. USD 33 billion), the highest level since 2014, led by large...